Tay-Sachs Disease Genotype: HEXA Mutations, Inheritance, and Testing

Tay-Sachs disease (TSD) is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the HEXA gene (chromosome 15q23-q24), encoding the α-subunit of β-hexosaminidase A (HexA).

Genotype-Phenotype Correlation

  • Classic infantile TSD: Two "null" alleles (no HexA activity) → onset 3–6 mo, death by age 4–5.
  • Juvenile TSD: One null + one residual activity allele (or two residual) → onset 2–10 yr, slower progression.
  • Late-onset TSD (LOTS): Two residual activity alleles (or compound heterozygote) → onset adolescence/adulthood; proximal weakness, ataxia, psychiatric; variable survival.

Common Pathogenic Variants

  • Ashkenazi Jewish: 1278insTATC (78%), IVS12+1G>C (20%), others rare.
  • French Canadian: Deletion 7.6 kb (exon 1–5) or IVS12+1G>C.
  • Cajun: 1278insTATC.
  • General population: Hundreds of private mutations; pseudodeficiency allele (R247W/R249W) reduces serum HexA but not activity vs. natural substrate.

Inheritance & Carrier Status

  • Carriers (heterozygotes): ~50% HexA activity; asymptomatic.
  • Carrier couple: 25% affected, 50% carriers, 25% unaffected non-carriers per pregnancy.
  • Pseudodeficiency allele complicates enzyme-based screening; molecular testing resolves.

Testing Strategies

  • Carrier screening: Targeted mutation panel (ethnic-specific) or full HEXA sequencing. Recommended pre-conception/prenatal for high-risk groups.
  • Prenatal diagnosis: CVS (10–13 wks) or amniocentesis (15–20 wks) → HexA activity + molecular confirmation.
  • Newborn screening: Not routine; some pilot programs.
  • Preimplantation genetic testing (PGT-M): For carrier couples undergoing IVF.

Genetic Counseling Essentials

  • Residual risk after negative targeted panel (pan-ethnic sequencing reduces).
  • Pseudodeficiency vs. true mutation distinction.
  • Reproductive options: natural + prenatal Dx, PGT-M, donor gametes, adoption.

Genetic Disorders - Related Articles